Kumar D, Kumari K, Jayaraj A, Kumar V, Kumar RV, Dass SK, Chandra R, Singh P. Understanding the binding affinity of noscapines with protease of SARS-CoV-2 for COVID-19 using MD simulations at different temperatures.
J Biomol Struct Dyn 2020;
39:2659-2672. [PMID:
32362235 PMCID:
PMC7212547 DOI:
10.1080/07391102.2020.1752310]
[Citation(s) in RCA: 37] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
The current outbreak of a novel coronavirus, named as SARS-CoV-2 causing COVID-19
occurred in 2019, is in dire need of finding potential therapeutic agents. Recently,
ongoing viral epidemic due to coronavirus (SARS-CoV-2) primarily affected mainland China
that now threatened to spread to populations in most countries of the world. In spite of
this, there is currently no antiviral drug/ vaccine available against coronavirus
infection, COVID-19. In the present study, computer-aided drug design-based screening to
find out promising inhibitors against the coronavirus (SARS-CoV-2) leads to infection,
COVID-19. The lead therapeutic molecule was investigated through docking and molecular
dynamics simulations. In this, binding affinity of noscapines(23B)-protease of SARS-CoV-2
complex was evaluated through MD simulations at different temperatures. Our research group
has established that noscapine is a chemotherapeutic agent for the treatment of drug
resistant cancers; however, noscapine was also being used as anti-malarial, anti-stroke
and cough-suppressant. This study suggests for the first time that noscapine exerts its
antiviral effects by inhibiting viral protein synthesis.
Collapse